Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Afinitor
Pharma
Merck's Welireg again comes up short in OS but excels in PFS
Merck’s Welireg continues to show benefits in PFS but no significant improvement in overall survival when compared to Novartis’ chemotherapy Afinitor.
Kevin Dunleavy
Sep 13, 2024 8:00am
At ESMO, Merck touts Welireg's potential in kidney cancer
Oct 21, 2023 9:00am
Merck looks to broaden Welireg's reach in kidney cancer
Aug 18, 2023 11:12am
Novartis' campaign tackles inequities in breast cancer health
Jun 14, 2021 8:00am
Chasing Novartis, Chi-Med posts neuroendocrine cancer win
Sep 30, 2019 9:55am
Novartis wins FDA nod for newly acquired cancer drug Lutathera
Jan 26, 2018 3:10pm
